Tag Archives: KRAS

← Older posts

Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs

Forma Therapeutics has developed a pipeline of small molecules aimed at rare blood disorders and cancers, but it aims to advance two—investigational treatments for sickle cell disease and for advanced prostate cancer—and find partners for the rest of them. Now the Watertown, MA-based company is considering tapping the public markets to add enough funds to […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs

Mirati Adds Execs With Commercial Experience at Spark, Bristol-Myers

Cancer drug developer Mirati Therapeutics is beefing up its leadership team as its lead programs advance through human testing. The San Diego-based company (NASDAQ: MRTX) this week added two executives to its C-suite as part of a strategic effort to ready the biotech for its potential transformation into a commercial company. For San Diego, it’s […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , | Comments Off on Mirati Adds Execs With Commercial Experience at Spark, Bristol-Myers

Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex

The KRAS gene has become a hot target for cancer research for a growing number of drug developers. Merck, which is already testing a KRAS vaccine candidate, is now spreading its bets with a licensing deal for small molecule KRAS drugs being developed by two Otsuka Pharmaceutical subsidiaries. Merck (NYSE: MRK) is paying $25 million […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex

Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More

For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the way. Targeted medicine isn’t new to lung cancer, but only a fraction of patients have […]

Posted in National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference on Lung Cancer in Barcelona this weekend a number of drug makers trotted out some of their latest advances in immunotherapy, targeted pills, drug combinations, and more. Xconomy rounded […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More

[Corrected 12:55 p.m. ET. See below.] Acquisitions made Pfizer what it is today: the world’s biggest drug maker measured by revenue. But as the company maps its future, CEO Albert Bourla is breaking some of that legacy apart. Blockbuster drugs such as Viagra, which was discovered in-house, and Lipitor, which came via acquisition, are currently […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More

After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs

In May, Amgen (NASDAQ: AMGN) revealed intriguing data from the first-ever human trial of a drug that targets tumors with a specific mutation to the gene KRAS, which occurs in about one-quarter of all cancers. Amgen showed 30 percent of lung cancer patients with the mutation saw their tumors shrink. Even though the data were […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs

ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight

The world’s biggest annual cancer conference is just around the corner. Data presented at the American Society of Clinical Oncology meeting each year can change medical practice and make or break companies whose drugs are under the microscope. That’s what makes even the “abstracts,” or snippets of data revealed a few weeks before the meeting, […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight

East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More

One of the year’s biggest cancer meetings took place this week in Barcelona, and many biotechs from the East Coast were angling for the spotlight. Some wowed investors, others, not so much. We’ve got the ups and downs and the rest of the week’s news and tidbits below: —Agios Pharmaceuticals (NASDAQ: AGIO) was one of […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More

Dicerna Prices Upsized IPO at $15 Per Share, Starts Trading Thursday

Dicerna Pharmaceuticals had little trouble raising cash from Wall Street investors late Wednesday. The Watertown, MA-based company has priced its IPO at $15 per share, blowing past its projected range of $11 to $13 per share. It sold 6 million shares in the offering, up from the 5 million it initially planned to sell. All […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on Dicerna Prices Upsized IPO at $15 Per Share, Starts Trading Thursday← Older posts